GOG-218 Study

The GOG-218 study was a clinical trial that evaluated the effectiveness of adding bevacizumab (a targeted cancer therapy) to standard chemotherapy for women with advanced ovarian cancer. It found that combining bevacizumab with chemotherapy improved progression-free survival, meaning patients lived longer without the cancer worsening. However, it also increased some side effects. The study helped determine that this combination can be beneficial for some patients, providing evidence for treatment options that may improve outcomes in advanced ovarian cancer management.